Rupatadine Ameliorates Cisplatin‐Induced Hepatotoxicity in Rats: Targeting HMGB1/TLR4/NF‐κB and NLRP3/Caspase‐1 Signaling Pathways
Journal of Biochemical and Molecular Toxicology · 2026-08 · 40 (8)
DOI: 10.1002/jbt.71050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 30.07.2026. Verfasst von Shaimaa Mohamed Abdelrahman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia, Egypt. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, HMGB1 Protein, Signal Transduction, Caspase 1. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite cisplatin (CISP) is broadly employed in cancer therapy, its adverse effects, involving hepatotoxicity, restrict its clinical usage. Thus, this study was designed to explore the prospect of repurposing rupatadine (RUPA), a dual antagonist of histamine and platelet‐activating factor (PAF), against CISP‐evoked hepatotoxicity in rats. Rats were i.p . injected with CISP (6 mg/kg) for the induction of hepatotoxicity on the 8th day of the study in the presence and absence of RUPA in two dosages (3, 6 mg/kg) orally for 14 days. Different biochemical parameters and histopathological assessments, along with the mechanistic characterizations of the possible protective impact of the RUPA were conducted. Administration of CISP evoked hepatic histopathological modifications and raised serum liver enzyme levels and hepatic MDA content, PAF, and histamine levels, along with diminishing the serum albumin level, hepatic SOD activity, and GSH level. Moreover, CISP remarkably augmented the levels of HMGB1, TLR4, p‐NF‐κB p65, IL‐6, TNF‐α, IL‐18, IL‐1β, NLRP3, and cleaved caspase‐1 proteins with an evident decline in the level of IL‐10. On the contrary, pretreatment with either RUPA.3 or RUPA.6 dramatically ameliorated these alterations triggered by CISP injection. RUPA counteracts hepatotoxicity evoked by CISP in rats via its anti‐oxidative as well as anti‐inflammatory properties via repression of hepatic HMGB1/TLR4/NF‐κB and thus restricts the activation of NLRP3/caspase‐1 signaling cascade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
- Department of Biochemistry, Faculty of Pharmacy, Minia National University, New Minia, Egypt.
ORCID-Profile: Olivia N Beshay
Zitieren
APA
Abdelrahman, S. M., Bekhit, A. A., & Beshay, O. N. (2026). Rupatadine Ameliorates Cisplatin‐Induced Hepatotoxicity in Rats: Targeting HMGB1/TLR4/NF‐κB and NLRP3/Caspase‐1 Signaling Pathways. Journal of Biochemical and Molecular Toxicology, 40(8). https://doi.org/10.1002/jbt.71050
Vancouver
Abdelrahman SM, Bekhit AA, Beshay ON. Rupatadine Ameliorates Cisplatin‐Induced Hepatotoxicity in Rats: Targeting HMGB1/TLR4/NF‐κB and NLRP3/Caspase‐1 Signaling Pathways. Journal of Biochemical and Molecular Toxicology. 2026;40(8). doi:10.1002/jbt.71050
BibTeX
@article{Abdelrahman2026,
author = {Abdelrahman, Shaimaa Mohamed and Bekhit, Amany Abdlrehim and Beshay, Olivia N},
title = {Rupatadine Ameliorates Cisplatin‐Induced Hepatotoxicity in Rats: Targeting HMGB1/TLR4/NF‐κB and NLRP3/Caspase‐1 Signaling Pathways},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
volume = {40},
number = {8},
doi = {10.1002/jbt.71050}
}
EUVIMED